Galena Biopharma, Inc. (GALE): Ryan Dunlap , Former Chief Financial Officer of Galena Biopharma, Inc. sold 126,875 shares on Jun 1, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $2.18 per share for a total value of $276,587.50 , the company said in a SEC Form 4 Filing.
Galena Biopharma Inc: On Friday, Jun 3, 2016 heightened volatility was witnessed in Galena Biopharma Inc which led to swings in the share price. The shares opened for trading at $2.05 and hit $2.18 on the upside , eventually ending the session at $2.12, with a gain of 1.44% or 0.03 points. The heightened volatility saw the trading volume jump to 31,52,950 shares. The 52-week high of the share price is $2.39 and the company has a market cap of $385 M . The 52-week low of the share price is at $0.5855.
Galena Biopharma Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapeutics. Its development portfolio ranges from mid- to late-stage clinical assets including immunotherapy program led by its lead product NeuVax (nelipepimut-S) which is in Phase III clinical trial and is a targeted cancer immunotherapy. NeuVax is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein a target for therapeutic intervention in breast and gastric carcinomas. GALE-301 is an immunogenic peptide and can stimulate cytotoxic T lymphocytes to recognize and destroy Folate Binding Protein-expressing cancer cells. GALE-401 is a controlled release formulation of anagrelide. Its commercial drug Abstral (fentanyl) Sublingual Tablets is a treatment option for inadequately controlled breakthrough cancer pain.